Science & discoveries / Randomised study · phase 3
R21/Matrix-M: what the malaria vaccine trial taught us
A large study in children across four African countries.
Key takeaway
A vaccine result must be read alongside location, age and follow-up period.
What was studied
The phase 3 trial examined R21/Matrix-M in Burkina Faso, Mali, Kenya and Tanzania. More than five thousand children were randomly assigned to the candidate vaccine or comparison group in a double-blind study.
What was found
The paper reported protection against clinical malaria during the assessment period and analysed seasonal-transmission sites separately from those with more continuous transmission. This distinction helps explain why the epidemiological context matters.
What it does not prove
Protection is not absolute. The conclusions do not translate directly into the same result for every age or region. Exposure risk and time since vaccination influence the practical meaning of the effect.
Why it matters
The development matters because it could reduce disease burden in children where malaria circulates. This article explains the 2024 trial; it is not individual travel-vaccination advice in Albania.
Sources
- Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial ↗The Lancet · Datoo and colleagues · Accessed 5 September 2026
An editorial explanation referring to the listed sources. General information; individual interpretation and treatment require clinical assessment.
Updated 5 September 2026. How we prepare our content